<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453271</url>
  </required_header>
  <id_info>
    <org_study_id>NB-002-002</org_study_id>
    <nct_id>NCT00453271</nct_id>
  </id_info>
  <brief_title>Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoBio Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoBio Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and
      effective in the treatment of distal subungual onychomycosis of the toenail.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and
      effective in the treatment of distal subungual onychomycosis of the toenail.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Planimetry assessment of the target great toenail</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complete cure</measure>
    <time_frame>Week 46</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of therapeutic success</measure>
    <time_frame>Week 46</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's visual assessment of length of new unaffected nail</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence/absence of DSO on all toenails</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>NB-002 0.25% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-002 0.5% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-002 0.5% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NB-002</intervention_name>
    <arm_group_label>NB-002 0.25% BID</arm_group_label>
    <arm_group_label>NB-002 0.5% QD</arm_group_label>
    <arm_group_label>NB-002 0.5% BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle control</intervention_name>
    <arm_group_label>Vehicle control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are healthy males or females between the ages of 18 and 75 years of age;

          -  have a clinical diagnosis of mild to moderate DSO in the nail of at least one great
             toe, involving 25%-67% of the nail, without lunular or proximal involvement;

          -  positive mycology results (ie, KOH test and culture of a dermatophyte) from the target
             great toenail;

          -  refrain from using any lotions, creams, liquids, or polish on treated toenails or on
             the skin immediately adjacent to the toenails during the treatment period unless
             directed to do so by the investigator;

          -  are willing to refrain from using topical steroids or topical antifungals on toenails
             or the skin immediately adjacent to the toenails; or systemic antifungals for the
             duration of the study;

        Exclusion Criteria:

          -  females who are pregnant, plan to become pregnant during the study, or are nursing a
             child;

          -  are hypersensitive to topical creams, ointments, medications, or surfactants;

          -  have received systemic antifungal therapy for any reason within 3 months, or topical
             antifungal therapy on the toenails or skin immediately adjacent to the toenails within
             3 weeks prior to the start of the study; or

          -  have taken any investigational drug within 4 weeks prior to the start of the study.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia Barba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Dermatology Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Bucko, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Dermatology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Pollak, DPM, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endeavor Clinical Trials, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Jarratt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J &amp; S Studies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Kaylor, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Welborne Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kempers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Clinical Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Matheson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Medical Research Center, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brock McConnehey,, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest Clinical Trial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Pariser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phoebe Rich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Dermatology and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Stewart, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Center for Research Corp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Swinyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Research Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Bissonette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovaderm Research Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvia Garnis-Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EntraLogix Clinical Group Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gratton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Dermatology Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lyn Guenther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Guenther Dermatology Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rod Kunynetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ultranova Skincare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lynde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynderm Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Langley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Canada Cutaneous Research Associates, LTD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>K. Papp Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Poulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Reeberche Dermatologique du Quebec Metropolitain (CRDQ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Gulliver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newlab Clinical Research Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R G Sibbald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Dermatology Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trial</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welborne Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Corp.</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies, Inc.</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newlab Clinical Research, Inc.</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates, LTD</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research, Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinic</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4Y 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EntraLogix Clinical Group, Inc.</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1U4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Reeberche Dermatologique du Quebec Metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <disposition_first_submitted>May 15, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2013</disposition_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic persistent infection of the nail bed or plate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

